Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immutep (IMMP)
NASDAQ:IMMP
IMMP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.66 - $3.34
Previous CloseN/A
Volume50.42K
Average Volume (3M)71.58K
Market Cap
$291.38M
Enterprise Value$124.09M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 27, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding145,558,960
10 Day Avg. Volume67,270
30 Day Avg. Volume71,582
Standard Deviation0.21
R-Squared0.30
Alpha-0.00261
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.00Price Target Upside525.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Immutep News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsImmutep reported positive updated data from cohort B of the P2b TACTI-003 study evaluating efti + Keytruda in 1L head & neck cancer with negative PD-L1 expression, showing promising results.
Market OpportunityThe TACTI-004 trial could open up a very large market opportunity for IMMP, as it will be enrolling first line squamous and non-squamous NSCLC patients who are unselected for PD-L1 expression.
Bears Say
Market CompetitionThe 1L metastatic HNSCC space has become very competitive.
---
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.58% Other Institutional Investors
98.91% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $1.66 and its highest was $3.33 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is $291.38M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Aug 27, 2025 which is in 184 days.
How were Immutep’s earnings last quarter?
Currently, no data Available
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.14.
How many shares outstanding does Immutep have?
Immutep has 145,558,960 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in IMMP
---
Immutep Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (525.00% Upside)
$12.00 (525.00% Upside)
Blogger Sentiment
Bullish
IMMP Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.90%
12-Months-Change
Fundamentals
Return on Equity
-25.75%
Trailing 12-Months
Asset Growth
37.16%
Trailing 12-Months
Company Description
Immutep
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
---
IMMP Stock 12 Month Forecast
Average Price Target
$12.00
▲(525.00% Upside)
Technical Analysis
Best Analysts Covering IMMP
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-36.11%
reiterated a buy rating 5 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -36.11% per trade.
---